BOT 5.26% 36.0¢ botanix pharmaceuticals ltd

Ann: FDA Approves Sofdra, page-504

  1. 166 Posts.
    lightbulb Created with Sketch. 48
    Agree. Stock is under pressure. Even though you get killed in here for saying it.

    I don’t mind the CR or the timing of it, and it’s held firm above strike. Management did a decent job and grabbed the cash when they could, incentivising new investors with very attractive pricing and timing.

    whether that’s why or not, the fact remains, the stock is now under pressure.
    Last edited by wilddman: 10/07/24
 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.